Stock Track | Schrodinger Soars 5.39% as Strong Software Growth and Promising Outlook Outweigh Revenue Decline

Stock Track02-27

Schrodinger Inc. (SDGR) shares surged by 5.39% in intraday trading on Thursday, driven by the company's robust Q4 2024 earnings report and analysts' optimism about its growth prospects.

Despite a decline in overall revenue for the full year 2024, Schrodinger reported impressive growth in its software business during the fourth quarter. Software revenue increased by 16% year-over-year to $79.7 million, while drug discovery revenue also saw a significant jump to $8.7 million, up from $5.5 million in Q4 2023.

Analysts from Piper Sandler and TD Cowen reaffirmed their Buy and Overweight ratings on SDGR, citing the company's strong software performance, new collaborations with leading pharmaceutical companies, and plans to launch new products, including predictive toxicology technology and enhancements to biologics discovery technologies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment